Axicabtagene Ciloleucel Clinical Trials
10 recruitingBiologic
Phase 26Phase 12Phase 31Phase 41
Showing 1–10 of 10 trials
Recruiting
Phase 2
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Follicular Lymphoma
M.D. Anderson Cancer Center20 enrolled1 locationNCT06043323
Recruiting
Phase 2
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+3 more
City of Hope Medical Center56 enrolled1 locationNCT07042438
Recruiting
Phase 3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
Kite, A Gilead Company300 enrolled90 locationsNCT05605899
Recruiting
Phase 1
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
HIV InfectionRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+11 more
AIDS Malignancy Consortium20 enrolled5 locationsNCT05077527
Recruiting
Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network396 enrolled87 locationsNCT05633615
Recruiting
Phase 2
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea45 enrolled15 locationsNCT07254754
Recruiting
Phase 2
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Large B-cell Lymphoma
Marcela V. Maus, M.D.,Ph.D.28 enrolled2 locationsNCT06550141
Recruiting
Phase 1
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
Non-Hodgkin LymphomaLarge B-cell Lymphoma
Stanford University20 enrolled1 locationNCT05794958
Recruiting
Phase 2
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
LymphomaFollicular LymphomaRefractory Lymphoma
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT06826118
Recruiting
Phase 4
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Lymphoma, B-Cell
Zhengzhou University20 enrolled1 locationNCT06609304